What is EBS's current stock price?

EBS is currently trading at $8.99 with a daily change of +10.31%. Visit StocksRunner for live updates.

What are EBS stock's key strengths?

EBS current strengths include: Expands stock buyback program, Earnings are forecast to grow, Upgraded on attractively valued. These are updated in real time by the StocksRunner IQ algorithm.

What are the risks associated with EBS stock?

Current risk factors for EBS include: Low. Risk levels are assessed by StocksRunner based on volatility, sector strength, volume, and investor confidence.

What is EBS's current StocksRunner IQ Score?

EBS current StocksRunner IQ Score is: Strong Sell. This score reflects aggregated earnings data, news sentiment, analyst ratings, and market momentum as of the latest update.

What factors influence EBS's StocksRunner IQ Score?

EBS StocksRunner IQ Score is a composite Credibility Score that weighs: quarterly earnings results vs. analyst expectations, breaking news sentiment and headline credibility, Wall Street analyst price target consensus, trading volume and price momentum, and sector-level risk indicators. All factors are aggregated in real time.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

EBS Stock Analysis & IQ Rating | Emergent Biosolution

Q: Should I buy EBS stock right now?

StocksRunner does not provide personalized investment advice. Our IQ Credibility Score for EBS aggregates analyst sentiment, earnings performance, and news momentum to help you make an informed decision. The current IQ signal is: Strong Sell. Always consider your own risk tolerance and consult a financial advisor before investing.

Q: What does a Strong Buy rating mean for EBS?

A Strong Buy rating on StocksRunner indicates that the aggregated IQ score — drawing from earnings beats, analyst upgrades, and positive news sentiment — reflects high confidence in EBS near-term growth potential. It is the strongest signal in the StocksRunner IQ rating scale.

EBS

Emergent Biosolution

$8.99

+$0.84 | +10.31%

Set Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$14.06

MKT CAP

$468.38M

52W Low

$4.02

VOL

$2.05M

P/E Ratio

N/A

AVG VOL

$922.75K

RSI

32.81

TREND

Downtrend

EBS Stock IQ

Login to see Emergent Biosolution (EBS) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

EBS Target Price

Login to display

Strengths

EBS Rewards

Earnings are forecast to grow

EBS Rewards

Upgraded on attractively valued

EBS Rewards

Expands stock buyback program

Technical Indicators

EBS Technical Indicators

Oversold

EBS Price Performance

$11.54 (-22.10%)

$12.05 (-25.39%)

$9.92 (-9.38%)

$5.72 (+57.17%)

1year

6month

3month

1month

EBS Analysts Opinion

Overall standing based on market and analyst consensus. menu Hover over the category for more information

EBS Analysts opinion is negative and it remained unchanged from the past 3 months

EBS Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

86%

Consensus Rating

NA

Buy
Opinion

100%

Trend
Score

0%

Potential
Score

EBS Street Sentiment is extremely bullish but have mixed views on the near-term outlook

EBS Risk Level

EBS has Low risk level

Low

LOW

HIGH

EBS Performance Sentiment

Sentiments overview associated with events and the stock performance

86%

Positive

12 out of 14
events present

14%

Negative

2 out of 14
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Key Price Levels

Average key support and resistance price levels

Support Price

$8.15

Resistance Price

$13.90

Current Price Range

$8.99

$8.15

$13.90

Show methods +

Analyst Consensus

Recent Upgrades and Downgrades

100%

Consensus Rating

STRONG BUY

1

Buy

0

Hold

0

Sell

Date

Action

Rating

Firm

Dec 16, 2025

Reiterate

Buy

HC Wainwright & Co.

Runners Also Watch

Close Price

Change

CING

Cingulate Inc.

6.54

+4.31%

WVE

Wave Life Sciences

13.85

-0.57%

SNY

Sanofi

47.66

-2.06%

NVS

Novartis AG

166.87

-1.04%

COCP

Cocrystal Pharma

1.05

+1.94%

EBS Latest Analysis +

Emergent BioSolutions plummets on weak 2026 revenue guidance Q4 results.

Fri Feb 27, 2026

$8.15 | -26.58%

Potential

Emergent BioSolutions authorizes $50 million stock repurchase program.

Thu Feb 26, 2026

$11.10 | +0.82%

Activity

Emergent Biosolutions Non-GAAP EPS of -$0.43 misses by $0.54 revenue of $148.7M misses by $68.8M.

Thu Feb 26, 2026

$11.10 | +0.82%

Earnings

Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada Strengthening Canadas Leadership in Health Preparedness. WINNIPEG Manitoba Feb. 26 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS) today announced a series of new contracts and a contract modification with the Public Health Agency of Canada (PHAC) and the Department of National Defence (DND) to deliver critical medical countermeasures to support Canada'.s biological threat pr

Thu Feb 26, 2026

$11.10 | +0.82%

Activity

How did Mewgenics become a Steam phenomenon? #gaming. Rapid rise from cult project to breakout hit A hand sized indie release captured extraordinary attention almost overnight. The games blend of tactical turn based combat bizarre humor and deep emergent systems drew a vast audience and early metrics show it shattered established concurrent

Thu Feb 19, 2026

$10.99 | +1.95%

Momentum

Emergent BioSolutions Wins FDA Approval For New Narcan Multipacks To Expand Overdose Access. EBS) stock rose Friday following the FDA multipack configurations of over-the-counter NARCAN Nasal Spray.Emergent BioSolutions announced that the United States Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for new 6-count and 24-count multipack configurations of NARCAN Nasal Spray.NARCAN Naloxone HCl Nasal Spray 4 mg is the first FDA-approved over-the-count

Fri Feb 13, 2026

$10.83 | -0.14%

Activity

Emergent BioSolutions Receives United States FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks. GAITHERSBURG Md. Feb. 12 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE: EBS) announced that the United States Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for new multipack configurations of over-the-counter (OTC) NARCAN® Nasal Spray. This approval expands the NARCAN® Nasal Spray product suite to inc

Thu Feb 12, 2026

$10.85 | -1.63%

Activity

ARWR: Strong Start for REDEMPLO Commercialization. By Business UpdateFirst Commercial Sales of REDEMPLO®Following its approval in November 2025 Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) recently announced encouraging news from the early commercial launch of REDEMPLO (plozasiran) as a treatment for adults suffering from familial chylomicronemia syndrome (FCS). Even with the Thanksgiving Christmas and New Years holidays the company reported that over 100 prescriptions for REDEMPLO have been rec

Wed Feb 11, 2026

$11.03 | -0.14%

Activity

FAQ About EBS Stock Insights

What is EBS current stock price?

What are EBS stock strengths?

What is EBS Risk Level?

What is EBS market cap and volume?

What is EBS current Stock IQ?

Should I buy EBS stock right now?

Is EBS a Strong Buy right now?

What does a 'Strong Buy' rating mean for EBS?

What does a 'Strong Sell' rating mean for EBS?

What factors influence EBS's Stock IQ?

Explore our EBS Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored EBS Stock Strategies
Effective Risk Management

FIND US ON

Receive our EBS Daily Alerts

Join our subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

EBS

Emergent Biosolution

Set Alerts

Current Price

$8.99

+$0.84 | +10.31%

52W High

$14.06

MKT CAP

$468.38M

52W Low

$4.02

VOL

$2.05M

P/E Ratio

N/A

AVG VOL

$922.75K

RSI

32.81

TREND

Downtrend

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Runners Also Watch

Symbol

Close

Change

CING

Cingulate Inc.

6.54

+4.31%

WVE

Wave Life Sciences

13.85

-0.57%

SNY

Sanofi

47.66

-2.06%

NVS

Novartis AG

166.87

-1.04%

COCP

Cocrystal Pharma

1.05

+1.94%

EBS Price Performance

$11.54 (-22.10%)

$12.05 (-25.39%)

$9.92 (-9.38%)

$5.72 (+57.17%)

1year

6month

3month

1month

EBS Analysts Opinion

Overall standing per market and analyst expectations. menu Hover over the category for more information

EBS Analysts opinion is negative and it remained unchanged from the past 3 months

EBS Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

86%

Consensus Rating

NA

Buy
Opinion

100%

Trend
Score

0%

Potential
Score

EBS Street Sentiment is extremely bullish but have mixed views on the near-term outlook

EBS Risk Level

EBS has Low risk level

Low

LOW

HIGH

EBS Performance Sentiment

Sentiments overview associated with events and the stock performance.

86%

Positive

12 out of 14
events present

14%

Negative

2 out of 14
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Key Price Levels

Average key support and resistance price levels

Support Price

$8.15

Resistance Price

$13.90

Current Price Range

$8.99

$8.15

$13.90

Show methods +

Latest Analyst Actions

Overall Wall Street Rating

100%

Consensus Rating

STRONG BUY

1

Buy

0

Hold

0

Sell

Date

Action

Rating

Firm

Dec 16, 2025

Reiterate

Buy

HC Wainwright & Co.

EBS Stock IQ

Login to unlock Emergent Biosolution (EBS) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

Target Price

Login to display

Stock Insights

Strengths

EBS Rewards

Earnings are forecast to grow

EBS Rewards

Upgraded on attractively valued

EBS Rewards

Expands stock buyback program

Technical Indicators

EBS Technical Indicators

Oversold

EBS Latest Analysis

Emergent BioSolutions plummets on weak 2026 revenue guidance Q4 results.

Fri Feb 27, 2026

$8.15 | -26.58%

Potential

Emergent BioSolutions authorizes $50 million stock repurchase program.

Thu Feb 26, 2026

$11.10 | +0.82%

Activity

Emergent Biosolutions Non-GAAP EPS of -$0.43 misses by $0.54 revenue of $148.7M misses by $68.8M.

Thu Feb 26, 2026

$11.10 | +0.82%

Earnings

Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada Strengthening Canadas Leadership in Health Preparedness. WINNIPEG Manitoba Feb. 26 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS) today announced a series of new contracts and a contract modification with the Public Health Agency of Canada (PHAC) and the Department of National Defence (DND) to deliver critical medical countermeasures to support Canada'.s biological threat pr

Thu Feb 26, 2026

$11.10 | +0.82%

Activity

How did Mewgenics become a Steam phenomenon? #gaming. Rapid rise from cult project to breakout hit A hand sized indie release captured extraordinary attention almost overnight. The games blend of tactical turn based combat bizarre humor and deep emergent systems drew a vast audience and early metrics show it shattered established concurrent

Thu Feb 19, 2026

$10.99 | +1.95%

Momentum

Emergent BioSolutions Wins FDA Approval For New Narcan Multipacks To Expand Overdose Access. EBS) stock rose Friday following the FDA multipack configurations of over-the-counter NARCAN Nasal Spray.Emergent BioSolutions announced that the United States Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for new 6-count and 24-count multipack configurations of NARCAN Nasal Spray.NARCAN Naloxone HCl Nasal Spray 4 mg is the first FDA-approved over-the-count

Fri Feb 13, 2026

$10.83 | -0.14%

Activity

Emergent BioSolutions Receives United States FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks. GAITHERSBURG Md. Feb. 12 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE: EBS) announced that the United States Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for new multipack configurations of over-the-counter (OTC) NARCAN® Nasal Spray. This approval expands the NARCAN® Nasal Spray product suite to inc

Thu Feb 12, 2026

$10.85 | -1.63%

Activity

Discover EBS Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of EBS. We're here to help you make informed investment decisions today.

FIND US ON

Receive our EBS Daily Alerts

Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

EBS Stock trends

EBS Stock performance

EBS Stock analysis

EBS investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing EBS

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing EBS

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

EBS Stock Analysis & IQ Rating | Emergent Biosolution

EBS Stock IQ

EBS Target Price

EBS Analysts Opinion

EBS Street Sentiment

EBS Risk Level

EBS Performance Sentiment

Key Price Levels

Analyst Consensus

Explore our EBS Stock insights

Receive our EBS Daily Alerts

EBS Street Sentiment

EBS Risk Level

Key Price Levels

Latest Analyst Actions

Discover EBS Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of EBS. We're here to help you make informed investment decisions today.

Receive our EBS Daily Alerts

EBS Alerts